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Patients with Recessive Dystrophic Epidermolysis
Bullosa Develop Squamous-Cell Carcinoma
Regardless of Type VII Collagen Expression
Celine Pourreyron1, Georgie Cox1,2, Xin Mao1, Andreas Volz4, Nuzhat Baksh1, Tracy Wong1,2,
Hiva Fassihi2, Ken Arita2, Edel A. O’Toole1, Jorge Ocampo-Candiani6, Mei Chen5, Ian R. Hart3,
Leena Bruckner-Tuderman4, Julio C. Salas-Alanis6, John A. McGrath2, Irene M. Leigh1 and Andrew P. South1
Recent data suggest that individuals with recessive dystrophic epidermolysis bullosa (RDEB) only develop
squamous-cell carcinoma (SCC) in the presence of the NC1 domain of type VII collagen. This conclusion was
based on experimental work in which cryosections of SCCs from 10 people with RDEB all showed positive type
VII collagen immunostaining and observations in a murine model of SCC development in which tumors only
occurred using keratinocytes from RDEB subjects that expressed detectable levels of the NC1 domain of the
type VII collagen protein. To assess whether the clinical interpretation was valid in another cohort of RDEB
patients, we examined expression of type VII collagen in 17 SCC tumors excised from 11 patients. Indirect
immunofluorescent staining of SCC cryosections and Western blotting of cultured keratinocyte lysates
identified two RDEB individuals who did not express detectable levels of type VII collagen. Mutation analysis
revealed that these two patients harbor compound heterozygous nonsense mutations within the region of the
COL7A1 gene encoding the NC1 domain. These data suggest that individuals with RDEB can develop SCC
regardless of type VII collagen expression and that additional factors have a role in explaining the high
incidence of tumors complicating this genodermatosis.
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INTRODUCTION
Epidermolysis bullosa (EB) is a heterogeneous group of skin
disorders associated with blisters, erosions, and chronic
wounds. Among the subtypes of EB, dystrophic EB can be
either dominantly (DDEB) or recessively (RDEB) inherited
and is caused by mutations in the type VII collagen gene,
COL7A1 (reviewed by Varki et al., 2007). Type VII collagen is
the main component of anchoring fibrils, attachment
structures within the basement membrane between the
epidermis and the dermis (Uitto et al., 1992; Burgeson,
1993). The COL7A1 gene is approximately 32 kb in size and
contains 118 exons (Christiano et al., 1994). Over 250
mutations (point mutations, deletions, insertions) in COL7A1
have been identified in dystrophic EB. To some extent, the
severity of blistering and epidermal involvement can be
correlated with the mutation profile in COL7A1 (Jarvikallio
et al., 1997). In mild forms of dystrophic EB, mutated type VII
collagen is secreted but the morphology of the anchoring
fibrils is abnormal (Bruckner-Tuderman et al., 1999). In the
more severe subtypes, especially the Hallopeau–Siemens
form of RDEB, type VII collagen is very poorly expressed or
absent (McGrath et al., 1993).
Individuals with dystrophic EB are at greater risk of
developing squamous-cell carcinoma (SCC) than other EB
patients. This risk appears to correlate with the severity of skin
blistering, with 55% of Hallopeau–Siemens RDEB subjects
dying from metastatic SCC by the age 40 years (Fine et al.,
1999). Research over the past 14 years supports the
hypothesis that the severity of the disease is inversely
proportional to the amount of functional type VII collagen
expression present in the skin (McGrath et al., 1993;
Christiano et al., 1994). However, the dogma that less type
VII collagen leads to more severe disease coupled with a
greater risk of SCC was challenged by a recent paper in
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Science (Ortiz-Urda et al., 2005). In this report, the authors
demonstrated that type VII collagen, and more precisely the
NC1 domain, is required for Ras-driven skin SCC develop-
ment (Ortiz-Urda et al., 2005). RDEB patients in this study
who did not express detectable levels of type VII collagen
failed to develop SCC and keratinocytes isolated from these
patients did not form SCC in the experimental model. This
observation has significant implications for patient monitor-
ing and counseling as it suggests that individuals with the
most severe forms of RDEB may not be predisposed to
developing SCC.
In this study, we determined if there is a correlation
between RDEB SCC development and type VII collagen
expression. Therefore, we studied type VII collagen expres-
sion in 11 unrelated RDEB patients who had developed SCC.
We found that, in our cohort of patients, RDEB SCC develops
regardless of type VII collagen expression. Mutation analysis
revealed that patients who did not express detectable type VII
collagen were compound heterozygotes for nonsense muta-
tions within the NC1 coding domain of the COL7A1 gene. In
addition, we were unable to detect Ras gene mutations by
direct sequencing of DNA isolated from cultured SCC
keratinocytes.
RESULTS
Immunofluorescence microscopy identifies RDEB patients
who have developed SCC but who are negative for type VII
collagen expression
We first examined type VII collagen expression in non-EB
SCC frozen tumors using immunostaining of cryosections
with a commercially available polyclonal antibody raised
against the NC1 domain of type VII collagen. In sections from
20/20 non-EB SCC tumors, we saw type VII collagen
expression restricted to the basement membrane (Figure 1a).
We then examined type VII Collagen expression in 16
separate SCC tumors excised from 10 individual RDEB
patients. In 8/10 patients (13 tumors), we observed type VII
collagen expression. In the remaining 2/10 patients (three
tumors), we saw no detectable type VII collagen expression
(Figure 1b). We then examined type VII collagen expression
a
b
Figure 1. Immunofluorescence staining of RDEB SCC tumors reveals the presence or absence of type VII collagen immunoreactivity. Cryosections were
stained with antibodies to the type VII collagen NC1 domain (red) and desmoplakin (green). DAPI (blue) was used for nuclear staining. (a) Representative data
from 20 non-EB SCC tumors all of which showed positive staining for type VII collagen. (b) Top panel: representative data from 13 RDEB SCC tumors showing
positive staining for type VII collagen (left¼RDEB7-SCC3, middle¼RDEB8-SCC1, right¼RDEB9-SCC1). (b) Bottom panel: three RDEB SCC tumors
from two patients negative for type VII collagen staining (left¼RDEB1-SCC1, middle¼RDEB1-SCC2, right¼RDEB2-SCC1). Bar¼ 200mm.
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in normal skin or, where possible, keratinocytes isolated from
normal skin from nine RDEB patients. Either immunostaining,
immunoblotting from isolated keratinocytes or both experi-
mental techniques using non-SCC skin from nine out of nine
of our RDEB patients gave an identical pattern of type VII
collagen expression as seen in SCC tumors (Figure 2).
Immunoblotting of SCC keratinocyte lysates confirms
immunohistochemical results: RDEB patients who do not
express type VII collagen can develop SCC
Next, we isolated keratinocytes from non-EB SCC tumors and
six RDEB SCC tumors isolated from six patients; five of these
tumors were analyzed by immunohistochemistry (as above).
Lysates were prepared and immunoblotting was performed
using an affinity-purified polyclonal antibody raised against
recombinant NC1 domain of type VII collagen (Chen et al.,
1997). The pattern of type VII collagen expression seen with
frozen sections of normal skin and SCC tissue from both
RDEB and non-EB individuals were confirmed by these
experiments (Figure 3a and b), thus two of six RDEB patient
SCC keratinocytes did not express type VII collagen.
COL7A1 mutation analysis correlates with nonsense mutations
within the NC1 domain in patients lacking type VII collagen
expression
Direct sequencing of all 118 exons of the COL7A1 gene
revealed R525X and Q905X mutations in DNA from patient
RDEB2 (data not shown). Mutation analysis of the remaining
RDEB patients has been described previously (Whittock et al.,
1999; Kern et al., 2006). Of the two RDEB patients who did
not express detectable type VII collagen only nonsense
mutations within the NC1 domain were found (Table 1). Of
the RDEB patients who did express detectable type VII
collagen and whose COL7A1 genotype had been determined,
all were found to harbor at least one missense, one non-
sense, or one mutation that predicts a premature termination
codon distal to the NC1 domain of the COL7A1 gene.
Real-time PCR analysis of COL7A1 relates to the level of
type VII collagen expression
Taqmans Gene Copy Number Assays were used to assess the
level of COL7A1 transcripts relative to GAPDH in cDNA
constructed from total RNA isolated from normal cultured
keratinocytes, as well as cultured keratinocytes from RDEB1-
SCC1, RDEB3-SCC1, RDEB6-SCC1, and non-EB-SCC1. RDEB
patient SCC keratinocytes showed less COL7A1 transcripts
relative to GAPDH than did normal keratinocytes and non
EB-SCC1, whereas patient RDEB1 keratinocytes that did not
express type VII collagen showed the lowest levels of
COL7A1 expression (Figure 3c).
No Ras mutations were found in DNA isolated from SCC
keratinocytes
We analyzed DNA isolated from RDEB SCC keratinocytes of
six subjects and DNA isolated from SCC keratinocytes of four
non-EB subjects by PCR amplification and direct sequencing
and did not find any mutations in codons 12, 13, or 61 of the
N, K, and Ha Ras genes (data not shown).
DISCUSSION
Patients with the most severe form of RDEB are predisposed
to a high rate of aggressive SCC, which is the main cause of
premature death in this disorder (Fine et al., 1999). The
severity of disease in individuals with RDEB is correlated
inversely with type VII collagen expression, with the most
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Figure 2. Expression pattern of type VII collagen. The expression pattern of
type VII collagen in normal skin and/or keratinocytes isolated from RDEB
patients who have developed SCC is identical to that seen in SCC tumors by
immunofluorescence and immunoblotting methodology. (a–c) Cryosections
were stained with antibodies to the type VII collagen NC1 domain (red) and
desmoplakin (green). DAPI (blue) was used for nuclear staining. a¼ non-EB
normal skin. b¼normal skin from patient RDEB9. c¼ normal skin from
patient RDEB1. d¼ type VII collagen negative control, normal skin.
Bar¼200 mm. (e) Immunoblotting of lysates from keratinocytes isolated from
normal skin using a purified polyclonal antibody to the NC1 domain of type
VII collagen. WISH¼human amniotic cell line. NC1¼ recombinant NC1
domain. RDEB11K, RDEB3K, RDEB1K¼ normal keratinocytes from patients
RDEB11, RDEB3, and RDEB1. Note negative immunofluorescence and
immunoblotting for type VII collagen in the normal skin or normal
keratinocytes isolated from patient RDEB1 who has developed two SCC
tumors during the course of this study.
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severely affected patients expressing little or no detectable
protein (Christiano et al., 1994). Recent data published in the
journal Science, have suggested that SCC can only develop in
the presence of the NC1 domain of type VII collagen (Ortiz-
Urda et al., 2005). If this is correct then RDEB patients with
no type VII collagen expression would be free from the life-
threatening complication of SCC and as such could be
counseled appropriately and monitored less frequently
for tumor development. In addition to clinical management,
if type VII collagen is essential for SCC development
this protein would become an attractive target for the
development of anticancer therapies.
In this study, we sought to clarify whether in our cohort of
RDEB patients only those that express type VII collagen
develop SCC. Two out of eight hsRDEB patients analyzed
here did not express type VII collagen and have gone on to
develop one or more SCC tumors. Lack of detectable type VII
collagen expression was confirmed using two independent
experimental methods and is supported by mutation analysis;
patients with no detectable type VII collagen are compound
heterozygous for nonsense mutations within the NC1 domain
coding portion of the COL7A1 gene.
SCC is a heterogeneous cancer characterized by multiple
genetic alterations (reviewed by Backvall et al., 2005). In
DNA isolated from 10 separate SCC keratinocyte populations
(six RDEB and four non-EB), we were unable to detect any
Ras mutations by direct sequencing. Although we cannot rule
out Ras-activating events in these SCC cells, these data
suggest that in these samples Ras mutations are not a major
event. Likewise, we cannot exclude that contributing
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Figure 3. Immunoblotting reveals the presence or absence of type VII collagen expression in primary keratinocytes isolated from RDEB SCC. Primary
keratinocytes were isolated from either normal skin, non-EB SCC, or RDEB SCC tissue and lysates were prepared as described. NC1¼ recombinant NC1 domain.
(a) Immunoblotting using affinity-purified polyclonal antibodies to the NC1 domain of type VII collagen shows expression from normal human keratinocytes and
two representative keratinocyte lysates from four separate non-EB SCC samples. (b) Immunoblotting using affinity-purified polyclonal antibodies to the NC1
domain of type VII collagen shows presence or absence of expression in RDEB SCC keratinocyte lysates. (c) TaqMans Gene Copy Number Assays for 50
COL7A1 mRNA sequence (Hs01574739_g1) and 30 COL7A1 mRNA sequence (Hs00982422_g1) relative to GAPDH relate to the level of type VII collagen
expression seen in a and b (n¼ 3;7SD). cDNA was synthesized from mRNA of RDEB SCC cells (RDEB1-SCC1, RDEB3-SCC1, and RDEB6-SCC1), non-EB SCC
cells (non-EB-SCC1), and normal keratinocytes (NHK1, NHK2).
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molecular events downstream of the Ras-driven oncogenesis
(described by Dajee et al. (2003) and Ortiz-Urda et al.
(2005)) have not been altered in the two patients described
here who do not express type VII collagen and therefore we
cannot speculate whether separate modes of tumor initiation
and progression exist. However, from this study we can
conclude that patients with RDEB who do not express
type VII collagen are still at risk of developing SCC and as
such these individuals should continue to be monitored
closely and investigated under the same clinical criteria as
RDEB patients who do express type VII collagen (Mallipeddi,
2002).
MATERIALS AND METHODS
Patients
This study was conducted according to the Declaration of Helsinki
Principles and was approved by the East London and City Health
Authority Research Ethics Committee and cooperating centres. The
RDEB diagnosis was confirmed by characteristic immunofluores-
cence findings and clinical criteria. In our cohort of 11 RDEB
patients, eight were diagnosed with Hallopeau–Siemens-type RDEB
(Hs-RDEB). After informed consent, biopsies from normal skin or
SCC tissue from non-EB and RDEB patients were obtained.
Tissue section preparation and immunohistochemistry
Skin or SCC tissue was washed immediately in phosphate-buffered
saline (PBS) before being embedded in OCT compound (VWR,
Lutterworth, UK) and snap-frozen in iso-pentane cooled by liquid
nitrogen. Cryosections (6mm thick) were re-hydrated in PBS for
2 minutes at room temperature before blocking of nonspecific
immunoreactive sites with 3% bovine serum albumin in PBS for
20 minutes at 371C. Sections were incubated in the primary
antibodies for 1 hour at 371C followed by three 5-minutes washes in
PBS. They were then incubated with secondary antibodies; goat
antimouse Alexa Fluore 488 conjugate and goat antirabbit Alex Fluore
568 conjugate (Molecular probes via Invitrogen, Paisley, UK) along
with the nuclear counterstain DAPI (Molecular Probes) for 45 minutes
at 371C. After three 5-minutes washes in PBS, sections were rinsed in
water, briefly air-dried and mounted with coverslips. Sections were
imaged using Nikon eclipse TE2000-S microscope within 18 hours.
Primary antibodies used were anti-collagen, type VII, human (rabbit
polyclonal supplied by Calbiochem, Via Merck Chemicals Ltd,
Nottingham, UK) and 115F (mouse monoclonal anti desomplakin I
and II, a generous gift from David Garrod, University of Manchester,
UK) (Parrish et al., 1987). As control, tissue sections were processed in
parallel without adding primary antibody. No reactivity for secondary
antibodies was observed on control histological sections.
Keratinocyte isolation and culture
Primary keratinocyte cultures were isolated following a standard
procedure (Rheinwald, 1989). Briefly, keratinocytes were obtained
from biopsies of normal skin and SCC tissue from non-EB and RDEB
individuals. After mechanical dissociation, the biopsy fragments
were immersed for 1 hour at 371C in a trypsin-EDTA solution. Then,
Table 1. Clinical features, COL7A1 genotype, and type VII collagen expression pattern of RDEB patients in this
study
Type VII collagen expression
SCC Normal skin
Patient Age Gender Mutation Diagnosis IMF WB IMF WB
RDEB1 35 F R525X/R578X hsRDEB    
 N/A
RDEB2 29 F R525X/Q905X hsRDEB    N/A
RDEB3 54 M 38321G4A/unknown hsRDEB + + + +
RDEB4 42 F 6075delC/unknown RDEB + + + N/A
RDEB5 33 F 3839delC/6501G4A RDEB + + N/A N/A
RDEB6 32 M 8244insC/8244insC hsRDEB N/A + N/A N/A
RDEB7 43 M R578X/7786delG hsRDEB + N/A + N/A
+ N/A
+ N/A
+ N/A
RDEB8 26 M 6501+1G4C/unknown hsRDEB + N/A + N/A
+ N/A
RDEB9 26 M 5572delG/G1703E RDEB + N/A + N/A
RDEB10 57 F Unknown hsRDEB + N/A + N/A
RDEB11 38 F G2073D/R578X hsRDEB + N/A + +
+ N/A
F, female; hsRDEB, Hallopeau–Siemens RDEB; IMF, immunostaining; M, male; N/A, sample not available; RDEB, recessive dystrophic epidermolysis
bullosa; SCC, squamous-cell carcinoma; WB, immunoblotting; , no expression of type VII collagen; +, expression of type VII collagen.
Multiple entries for SCC type VII collagen; expression for any given patient indicate multiple SCCs analyzed for that patient, that is, two SCC tumors
from patient RDEB1 were analyzed, whereas four SCC tumors from patient RDEB7 were analyzed. Age refers to development of first SCC tumor analyzed in
this study.
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the solution was filtered through a 100mm pore cell strainer (VWR)
and medium supplemented with 10% fetal bovine serum was added
to neutralized trypsin. Cells were isolated using a centrifuge
(5 minutes, 1000 r.p.m.) and the pellet was resuspended in normal
keratinocyte medium. Finally, the cells were seeded in T25 flasks
containing feeders. The keratinocytes were maintained in DMEM/
Ham’s F12 medium supplemented with 10% fetal bovine serum,
5mg/ml transferrin, 0.4 mg/ml hydrocortisone, 1010 M cholera toxin,
10 ng/ml EGF1, 5 mg/ml insulin, and 2 1011 M liothyronine. Fresh
feeder cells were added to the keratinocytes twice a week. Feeder
cells were NIH 3T3 cells treated with mitomycin (7 mg/ml during
3 hours).
COL7A1 mutation analysis
COL7A1 mutation analysis was performed previously or as
described (Whittock et al., 1999; Kern et al., 2006) except in the
case of patient RDEB2 where all 118 exons were analyzed by direct
sequencing.
Immunoblotting
Keratinocytes were cultured for 2 days in keratinocyte serum free
medium (Invitrogen) containing 1.2 mM CaCl2 and 150 mM ascorbic
acid. The cells were lysed with a chilled RIPA buffer containing
antiproteases. An aliquot of each lysate (22.5 mg for non-EB-SCC1,
non-EB-SCC2, RDEB1-SCC1, RDEB2-SCC1, and RDEB6-SCC1,
15 mg for normal human keratinocyte, RDEB3-SCC1, RDEB4-SCC1,
and RDEB5-SCC1) was resolved on a 5% SDS-polyacrylamide gel.
The fractionated proteins were transferred to Hybond-ECLTM nitro-
cellulose transfer membrane (Amersham Biosciences, Little Chalfont,
UK). The membrane was blocked with 10% non-fat milk-TTBS
during 2 hours at room temperature and incubated overnight at 41C
with a purified rabbit polyclonal antibody against Col VII NC1
domain (1/2,000) (Chen et al., 1997). Antibody–antigen complexes
were visualized by enhanced chemiluminescence (Amersham
Biosciences), according to the manufacturer’s instructions. As a
loading control, the same membrane was reprobed with a mouse
monoclonal antibody against human vinculin (1/10,000) (Sigma,
Poole, UK) during 1 hour at room temperature. The exposure times
were 5 minutes for collagen VII expression (using ECLþ ; Amersham
Biosciences) and 2 minutes for vinculin expression (using ECL,
Amersham Biosciences) for all samples.
mRNA isolation and Q-PCR
Total RNA was isolated from cultured cells using the RNAeasy
Minikit according to the manufacturer’s instructions (Qiagen,
Crawley, UK). cDNA was constructed using standard protocols.
Predesigned TaqMans Gene Expression assays, which analyze the
50 and 30 end of the COL7A1 transcript (Hs01574739_g1 and
Hs00982422_g1, respectively), were cycled on the 7900HT as per
manufacturer’s recommendations (Applied Biosystems, Foster City,
CA). Assays were set up in a total volume of 10.5 ml in 384-well clear
optical plates (Applied Biosystems) using the Biomek FX liquid
handling system (Beckmann Coulter, High Wycombe, UK) and data
were analyzed using SDSv2.3 (Applied Biosystems).
Ras mutation detection
DNA was isolated from cultured keratinocytes using Blood & Cell
Culture DNA Midi Kit (Qiagen) according to the manufacturer’s
instructions. Ras gene exons 1 and 2 were amplified either as one
PCR product or two as separate fragments for H-ras, K-ras, and N-ras,
using the following primers: Hrase 1F cagatggccctgccagcagc;
Hrase 2R catccaggacatgcgcagag; KRase 1F ggtactggtggagtatttg;
KRase 1R cagataacttaactttcagc; Krase 2F gttgttgagttgtatataac;
Krase 2R gcatggcattagcaaagac; N-rase 1F gtgaggccgatattaatccg;
N-rase 2R ctcatttccccataaagattc. Conditions for K-ras exons were
as follows: 95oC 2 minutes followed by 34 cycles of 951C
30 seconds, 551C 30 seconds, 721C 45 seconds. Conditions for
H- and N-ras genes were as follows: 951C 2 minutes followed by
34 cycles of 951C 30 seconds, 501C 30 seconds for N-ras or 651C for
H-ras, 721C 180 seconds. PCR products were directly sequenced
using BigDyeTM Terminator Cycle Sequencing Ready Reaction;
precipitated products were loaded onto an ABI/PE Biosystems
377 automated sequencer (ABI/PE, Warrington, UK).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank the patients for their involvement in this study as well as Charles
Mein, Trish Dopping-Hepenstal, and Catherine Jones for technical assistance,
and Lu Liu for the COL7A1 primers. This work was funded by DebRA UK and
DebRA Ireland.
REFERENCES
Backvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F
(2005) Genetic tumor archeology: microdissection and genetic hetero-
geneity in squamous and basal cell carcinoma. Mutat Res 571:65–79
Bruckner-Tuderman L, Hopfner B, Hammami-Hauasli N (1999) Biology of
anchoring fibrils: lessons from dystrophic epidermolysis bullosa. Matrix
Biol 1:43–54
Burgeson RE (1993) Type VII collagen, anchoring fibrils, and epidermolysis
bullosa. J Invest Dermatol 101:252–5
Chen M, Marinkovich MP, Veis A, Cai X, Rao CN, O’Toole EA et al. (1997)
Interactions of the amino-terminal noncollagenous (NC1) domain of type
VII collagen with extracellular matrix components. A potential role in
epidermal-dermal adherence in human skin. J Biol Chem 272:14516–22
Christiano AM, Anhalt G, Gibbons S, Bauer EA, Uitto J (1994) Premature
termination codons in the type VII collagen gene (COL7A1) underlie
severe, mutilating recessive dystrophic epidermolysis bullosa. Genomics
21:160–8
Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ et al. (2003)
NF-kappaB blockade and oncogenic Ras trigger invasive human
epidermal neoplasia. Nature 421:639–43
Fine JD, Johnson LB, Suchindran C, Bauer EA, Carter M, McGuire J et al.
(1999) Cancer and inherited epidermolysis bullosa: lifetable analyses of
the national epidermolysis bullosa registry study population. In: Fine JD,
Bauer EA, McGuire J, Moshell A (eds). Epidermolysis Bullosa. Clinical,
Epidemiologic and Laboratory Advances and the Findings of the
National Epidermolysis Bullosa Registry. Baltimore: The Johns Hopkins
University Press, 175–92
Jarvikallio A, Pulkkinen L, Uitto J (1997) Molecular basis of dystrophic
epidermolysis bullosa: mutations in the type VII collagen gene
(COL7A1). Hum Mutat 10:338–47
Kern JS, Kohlhase J, Bruckner-Tuderman L, Has C (2006) Expanding the
COL7A1 mutation database: novel and recurrent mutations and unusual
genotype-phenotype constellations in 41 patients with dystrophic
epidermolysis bullosa. J Invest Dermatol 126:1006–12
Mallipeddi R (2002) Epidermolysis bullosa and cancer. Clin Exp Dermatol
27:616–23
McGrath JA, Ishida-Yamamoto A, O’Grady A, Leigh IM, Eady RA (1993)
Structural variations in anchoring fibrils in dystrophic epidermolysis
www.jidonline.org 2443
C Pourreyron et al.
Type VII Collagen Expression in RDEB SCC
bullosa: correlation with type VII collagen expression. J Invest Dermatol
100:366–72
Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP et al. (2005) Type
VII collagen is required for Ras-driven human epidermal tumorigenesis.
Science 307:1773–6
Parrish EP, Steart PV, Garrod DR, Weller RO (1987) Antidesmosomal monoclonal
antibody in the diagnosis of intracranial tumours. J Pathol 153:265–73
Rheinwald JG (1989) Methods for Clonal Growth and Serial Cultivation of
Normal Human Epidermal Keratinocytes and Mesothelial Cells. Oxford:
IRL Press, 81–94
Uitto J, Chung-Honet LC, Christiano AM (1992) Molecular biology and
pathology of type VII collagen. Exp Dermatol 1:2–11
Varki R, Sadowski S, Uitto J, Pfendner E (2007) Epidermolysis bullosa. II. Type
VII collagen mutations and phenotype/genotype correlations in the
dystrophic subtypes. J Med Genet 44:181–92
Whittock NV, Ashton GH, Mohammedi R, Mellerio JE, Mathew CG, Abbs SJ
et al. (1999) Comparative mutation detection screening of the type VII
collagen gene (COL7A1) using the protein truncation test, fluorescent
chemical cleavage of mismatch, and conformation sensitive gel
electrophoresis. J Invest Dermatol 113:673–86
2444 Journal of Investigative Dermatology (2007), Volume 127
C Pourreyron et al.
Type VII Collagen Expression in RDEB SCC
